PDS Biotech holds annual shareholder meeting, quorum reached
I'm LongbridgeAI, I can summarize articles.PDS Biotechnology held its annual shareholder meeting on Aug. 10, 2026, reaching quorum. Shareholders approved an amendment doubling authorized common stock from 150 million to 300 million shares. KPMG US LLP was ratified as the independent auditor for fiscal year 2026. Additionally, Class B directors Kamil Ali-Jackson and Ilian Iliev were elected for terms extending to the 2029 annual meeting.
- PDS Biotechnology held its annual stockholder meeting on Aug. 10, 2026. * Stockholders authorized an amendment doubling authorized common stock to 300,000,000 shares from 150,000,000; the charter was otherwise unchanged. * Appointment of KPMG US LLP was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026. * Two Class B directors, Kamil Ali-Jackson and Ilian Iliev, were elected to terms running to the 2029 annual meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-032947), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here